Loading
A phase 1/2 trial of Durvalumab, Oleclumab, FOLFOX in colorectal cancer, run by MedImmune LLC, active and no longer recruiting.
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC is a phase 1/2 interventional study registered as NCT04068610 by MedImmune LLC, with 61 participants enrolled, started 2019-09-13 and due to reach its primary completion in 2022-10-10. Interventions recorded: Durvalumab, Oleclumab, FOLFOX, Bevacizumab. Conditions listed: Metastatic Microsatellite-stable Colorectal Cancer. Results were posted on ClinicalTrials.gov in 2023; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
61 enrolled.
95% CI 26.6 to 66.6; Figures from the ClinicalTrials.gov results section (first posted 2023-11-15), not from a publication · 95% CI 40.6 to 79.8
Source95% CI 11.9 to NA; Figures from the ClinicalTrials.gov results section (first posted 2023-11-15), not from a publication
Source95% CI 7.8 to 18.2; Figures from the ClinicalTrials.gov results section (first posted 2023-11-15), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in Part 2primary | Part 2 (C1): FOLFOX + Bevacizumab | 26 | 46.2% | - | 0.3173 | link |
| Part 2 (E1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab | 26 | 61.5% | ||||
| Overall Survival (OS) Per RECIST v1.1 in Part 1 | Part 1 (S1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab | 7 | 30.1 months | - | - | link |
| Progression-Free Survival (PFS) Per RECIST v1.1 in Part 1 | Part 1 (S1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab | 7 | 9.5 months | - | - | link |
Shares Durvalumab, Bevacizumab, Anti-angiogenic therapy, AstraZeneca.
Shares Durvalumab, Bevacizumab, Anti-angiogenic therapy, AstraZeneca.
Shares Durvalumab, Bevacizumab, Anti-angiogenic therapy, AstraZeneca.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Oleclumab, Durvalumab, AstraZeneca.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Durvalumab, Bevacizumab, AstraZeneca.
Shares Oleclumab, Durvalumab, AstraZeneca.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.